Jack N Hutter

发表

First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.

N. Waters, Z. Beck, G. Matyas, 2022, Vaccine.

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults

Linda A. Murray, N. Waters, E. Jongert, 2020, The Journal of infectious diseases.

An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model

P. Waterman, J. Moon, J. Livezey, 2020, Malaria Journal.

An Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine and Azithromycin Administered for Malaria Prophylaxis in Healthy Adults Challenged with 7G8 Chloroquine-Resistant Plasmodium falciparum in a Controlled Human Malaria Infection (CHMI) Model

P. Waterman, J. Moon, J. Livezey, 2020 .

Guidelines for the prevention of travel-associated illness in older adults

Christie A Joya, T. Whitman, Jennifer Masel, 2017, Tropical Diseases, Travel Medicine and Vaccines.

Initiation of anti-retroviral/Trimethoprim-Sulfamethoxazole therapy in a longitudinal cohort of HIV-1 positive individuals in Western Kenya rapidly decreases asymptomatic malarial parasitemia

V. A. Stewart, S. Luckhart, Carolyne M. Kifude, 2022, Frontiers in Cellular and Infection Microbiology.

Longitudinal and Cross-sectional Analyses of Asymptomatic HIV-1/Malaria Co-infection in Kisumu County, Kenya.

V. A. Stewart, S. Luckhart, Carolyne M. Kifude, 2022, The American journal of tropical medicine and hygiene.

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

S. Chaudhury, A. Lawrie, E. Bergmann-Leitner, 2021, PloS one.

Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials.

Paige E. Waterman, A. Spanier, P. Waterman, 2020, Vaccine.

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

J. Mascola, R. Koup, C. Andrews, 2023, The Lancet.

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV

L. Jagodzinski, A. Esber, I. Jani, 2021, Open Forum Infectious Diseases.

Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform

S. Peel, S. Chaudhury, C. Murray, 2021, medRxiv.

The CINAMR (Clinical Information Network-Antimicrobial Resistance) Project: A pilot microbial surveillance using hospitals linked to regional laboratories in Kenya: Study Protocol

P. Bejon, P. Turner, S. Dunachie, 2022, Wellcome open research.

Trial Evaluating Ambulatory Therapy of Travelers’ Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide

Akira A Shishido, J. Maguire, R. Deiss, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human Papillomavirus Infection-Core Concepts

C. Decker, Jack N Hutter, 2019 .

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.

Gregory D. Gromowski, S. Peel, M. Robb, 2023, The Lancet. Infectious diseases.

Bacteraemia due to Microbacterium paraoxydans in a patient with chronic kidney disease, refractory hypertension and sarcoidosis

P. McGann, J. Stam, K. Schaecher, 2018, JMM case reports.

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.

J. Mascola, Gregory D. Gromowski, S. Peel, 2024, The Lancet. Microbe.

Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial

L. Jagodzinski, M. Robb, M. Eller, 2024, Vaccines.